Kuros Biosurgery AG is pleased to announce that it has secured an option for a second round of venture capital financing to be exercised upon the achievement of certain key short-term milestones. When exercised, the new financing will enable the Company to extend its clinical trial activities in wound healing. In addition to existing investors the round will include three new investors from Switzerland and some of the Company’s employees. Kuros hopes to meet the relevant milestone and exercise the option later this year.

Including this option and corporate collaborations, Kuros has now secured a total of CHF 29.6m (€ 20m) in external financing to advance its technology and product development activities.